An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
Genetic diversity of HIV in Africa
HIV biological variability unveiled
Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
Factors associated with clinical progression in HIV-2 infected-patients
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects
Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France
Trends in HIV and sexual behaviour in a longitudinal study in a rural population in Tanzania, 1994–2000
Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes
Community randomized trials for HIV prevention
Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission
Association of hormonal contraception and HIV-seroprevalence in Nairobi, Kenya
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients
Intrafamilial transmission of HIV-1
Didanosine–ribavirin combination
Response to Soriano et al., ‘Treatment of chronic hepatitis C virus infection